Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Tumour-associated macrophages (TAMs) largely express an alternatively activated (or M2) phenotype, which entails immunosuppressive and tumour-promoting capabilities. Reprogramming TAMs towards a classically activated (M1) phenotype may thwart tumour-associated immunosuppression and unleash anti-tumour immunity. Here we show that conditional deletion of the microRNA (miRNA)-processing enzyme DICER in macrophages prompts M1-like TAM programming, characterized by hyperactive IFN-γ/STAT1 signalling. This rewiring abated the immunosuppressive capacity of TAMs and fostered the recruitment of activated cytotoxic T lymphocytes (CTLs) to the tumours. CTL-derived IFN-γ exacerbated M1 polarization of Dicer1-deficient TAMs and inhibited tumour growth. Remarkably, DICER deficiency in TAMs negated the anti-tumoral effects of macrophage depletion by anti-CSF1R antibodies, and enabled complete tumour eradication by PD1 checkpoint blockade or CD40 agonistic antibodies. Finally, genetic rescue of Let-7 miRNA activity in Dicer1-deficient TAMs partly restored their M2-like phenotype and decreased tumour-infiltrating CTLs. These findings suggest that DICER/Let-7 activity opposes IFN-γ-induced, immunostimulatory M1-like TAM activation, with potential therapeutic implications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Macrophages have been shown to be plastic [334,335,336].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [334]
Citations
Cites
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335
Regulation of microRNA biogenesis
Ha, M., & Kim, V. N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3838 · Cited by 5,462
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Cited by
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
Microenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847
Macrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Roles of IFN-γ in tumor progression and regression: A review
Jorgovanovic, D., Song, M., Wang, L., & Zhang, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00228-x · Cited by 1,234
“Recruited CTLs produced IFN-γ that was proven to be critical for sustaining M1 TAM activity and tumor inhibition [91].”
BackgroundPI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,173
Goodall, G. J., & Wickramasinghe, V. O. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00306-0 · Cited by 1,066
In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment
Chen, Q., Wang, C., Zhang, X., Chen, G., Hu, Q., Li, H., Wang, J., Wen, D., Zhang, Y., Lu, Y., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0319-4 · Cited by 1,010
DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25
Yang, L., Liu, Q., Zhang, X., Liu, X., Zhou, B., Chen, J., Huang, D., Li, J., Li, H., Chen, F., et al. (2020) · Nature · doi:10.1038/s41586-020-2394-6 · Cited by 965
Lee, W. S., Yang, H., Chon, H. J., & Kim, C. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00500-y · Cited by 688
Targeting macrophages in cancer immunotherapy
Duan, Z., & Luo, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00506-6 · Cited by 625
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Tie, Y., Tang, F., Wei, Y.-Q., & Wei, X.-W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01282-8 · Cited by 591
“DICER/Let-7 activity against IFN-γ-induced immunostimulatory M1-like TAM activation has potential therapeutic significance [212].”
BackgroundSchmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., Laoui, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9670 · Cited by 582
“RESULTS Combined ANGPT2 and VEGFA blockade provides marked survival benefits in both transgenic and transplant tumor models We studied tumor responses to combined or single ANGPT2 and VEGFA blockade in six mouse cancer models: (i) transgenic MMTVPyMTmice (FVB/nbackground),whichdevelopmetastatic breast cancer (6, 26);…”
BackgroundMethodInfluentialSelf-citationEngineering dendritic cell vaccines to improve cancer immunotherapy
Perez, C. R., & De Palma, M. (2019) · Nature Communications · doi:10.1038/s41467-019-13368-y · Cited by 505
Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246
Cooks, T., Pateras, I. S., Jenkins, L. M., Patel, K. M., Robles, A. I., Morris, J., Forshew, T., Appella, E., Gorgoulis, V. G., & Harris, C. C. (2018) · Nature Communications · doi:10.1038/s41467-018-03224-w · Cited by 482
Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments
Xu, J., Ding, L., Mei, J., Hu, Y., Kong, X., Dai, S., Bu, T., Xiao, Q., & Ding, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02325-5 · Cited by 389
“143 However, IFN-γ also induces the apoptosis of CD4+ T cells and reduces secondary antitumor immune responses.”
Cell-to-cell communication: microRNAs as hormones.
Bayraktar, R., Van Roosbroeck, K., & Calin, G. A. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12144 · Cited by 361
“Subsequently, we reported that the chromosome 13q14 region was deleted in more than 65% of Abbreviations CAAs, cancer-associated adipocytes; CAFs, cancer-associated fibroblasts; CLL, chronic lymphocytic leukemia; ECM, extracellular matrix; EVs, extracellular vesicles; FGF2, fibroblast growth factor 2; HDL, high-densit…”
BackgroundInfluentialThe Promise of Targeting Macrophages in Cancer Therapy
Brown, J. M., Recht, L., & Strober, S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3122 · Cited by 321
T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
Neubert, N. J., Schmittnaegel, M., Bordry, N., Nassiri, S., Wald, N., Martignier, C., Tillé, L., Homicsko, K., Damsky, W., Maby-El Hajjami, H., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3311 · Cited by 308
“Notably, 2G2 is a potent TAM-depleting agent, as shown previously in both transplant and transgenic cancer models (9, 31, 73).”
BackgroundInfluentialSelf-citationTailoring Nanomaterials for Targeting Tumor‐Associated Macrophages
Ovais, M., Guo, M., & Chen, C. (2019) · Advanced Materials · doi:10.1002/adma.201808303 · Cited by 298
Integrin CD11b activation drives anti-tumor innate immunity
Schmid, M. C., Khan, S. Q., Kaneda, M. M., Pathria, P., Shepard, R., Louis, T. L., Anand, S., Woo, G., Leem, C., Faridi, M. H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07387-4 · Cited by 300
Let‐7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer
Chirshev, E., Oberg, K. C., Ioffe, Y. J., & Unternaehrer, J. J. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0240-y · Cited by 253
“While tumor infiltration by TAMs with M1 phenotype have pro-inflammatory activity and better prognosis, the M2 phenotype is associated with increased angiogenesis and increased tumor burden [102].”
BackgroundCancer Stemness Meets Immunity: From Mechanism to Therapy
Chen, P., Hsu, W.-H., Han, J., Xia, Y., & DePinho, R. A. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108597 · Cited by 252
He, W., Kapate, N., Shields, C. W., & Mitragotri, S. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.12.001 · Cited by 236
Deng, R.-H., Zou, M.-Z., Zheng, D., Peng, S.-Y., Liu, W., Bai, X.-F., Chen, H.-S., Sun, Y., Zhou, P.-H., & Zhang, X.-Z. (2019) · ACS Nano · doi:10.1021/acsnano.9b02993 · Cited by 230
Macrophage targeting in cancer
Lopez‐Yrigoyen, M., Cassetta, L., & Pollard, J. W. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14377 · Cited by 221
Di Mitri, D., Mirenda, M., Vasilevska, J., Calcinotto, A., Delaleu, N., Revandkar, A., Gil, V., Boysen, G., Losa, M., Mosole, S., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.068 · Cited by 221
Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity
Hoves, S., Ooi, C.-H., Wolter, C., Sade, H., Bissinger, S., Schmittnaegel, M., Ast, O., Giusti, A. M., Wartha, K., Runza, V., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171440 · Cited by 219
“Flow cytometry revealed that the infiltrate of larger tumors (day 11) was dominated by a monocytic/TAM infiltrate, which we classified into three major subpopulations: TAM (CD11bF4/80Ly6CLy6G), monocytic MDSC (CD11b+F4/80−/lowLy6ChiLy6Gneg), and an MDSC–TAM intermediate population referred to as Ly6C MDSC (CD11b+F4/80…”
BackgroundMethodInfluentialSelf-citationLin, X., Wang, S., Sun, M., Zhang, C., Wei, C., Yang, C., Dou, R., Liu, Q., & Xiong, B. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0708-7 · Cited by 207
“It indicated that the Notch pathway plays pivotal roles in tumor EMT and macrophage alternative polarization in TME.”
BackgroundInfluentialRetractedChen, Y., Du, M., Yuan, Z., Chen, Z., & Yan, F. (2022) · Nature Communications · doi:10.1038/s41467-022-31932-x · Cited by 189
Classical and noncanonical functions of miRNAs in cancers
Dragomir, M. P., Knutsen, E., & Calin, G. A. (2022) · Trends in Genetics · doi:10.1016/j.tig.2021.10.002 · Cited by 191
Anti–PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment
Xiong, H., Mittman, S., Rodriguez, R., Moskalenko, M., Pacheco-Sanchez, P., Yang, Y., Nickles, D., & Cubas, R. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3208 · Cited by 197
Tumor-Associated Macrophage Status in Cancer Treatment
Malfitano, A. M., Pisanti, S., Napolitano, F., Di Somma, S., Martinelli, R., & Portella, G. (2020) · Cancers · doi:10.3390/cancers12071987 · Cited by 184
“miRNA modulation through the genetic deletion in macrophages of DICER, an enzyme fundamental for miRNA synthesis, was shown to inhibit tumor growth in preclinical models of breast, colon and lung tumors, reprogramming TAMs to express IFNγ and activate STAT1 proinflammatory signaling [57].”
BackgroundMolecular Profiling and Functional Analysis of Macrophage-Derived Tumor Extracellular Vesicles
Cianciaruso, C., Beltraminelli, T., Duval, F., Nassiri, S., Hamelin, R., Mozes, A., Gallart-Ayala, H., Ceada Torres, G., Torchia, B., Ries, C. H., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.008 · Cited by 180
“Because M1 andM2 TAM phenotypes correlate with anti- and pro-tumoral properties, respectively (Baer et al., 2016; Cassetta and Pollard, 2018; Mantovani et al., 2017), we asked whether the”
BackgroundMethodResultInfluentialSelf-citationPrecision Targeting of Tumor Macrophages with a CD206 Binding Peptide
Scodeller, P., Simón-Gracia, L., Kopanchuk, S., Tobi, A., Kilk, K., Säälik, P., Kurm, K., Squadrito, M. L., Kotamraju, V. R., Rinken, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14709-x · Cited by 179
Self-citationYin, C., Han, Q., Xu, D., Zheng, B., Zhao, X., & Zhang, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1601479 · Cited by 178
“Studies have shown that the activation of STAT3 signaling pathway mediated the M2-type polarization of macrophages,(32,33) while STAT1 signaling pathway mediated the polarization of M1-type macrophages.(33,34) Here, we”
BackgroundZhang, M., Huang, L., Ding, G., Huang, H., Cao, G., Sun, X., Lou, N., Wei, Q., Shen, T., Xu, X., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000308 · Cited by 172
Iron induces anti-tumor activity in tumor-associated macrophages
Costa da Silva, M., Breckwoldt, M. O., Vinchi, F., Correia, M. P., Stojanovic, A., Thielmann, C. M., Meister, M., Muley, T., Warth, A., Platten, M., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01479 · Cited by 164
“Thus, reprogramming macrophages in the TME could represent a promising therapeutic strategy to improve anti-tumor activity (19).”
BackgroundRe-Education of Macrophages as a Therapeutic Strategy in Cancer
Kowal, J., Kornete, M., & Joyce, J. A. (2019) · Immunotherapy · doi:10.2217/imt-2018-0156 · Cited by 161
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
The promising role of tumor-associated macrophages in the treatment of cancer
Wang, H., Wang, X., Zhang, X., & Xu, W. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101041 · Cited by 175
Zheng, Y., Han, Y., Sun, Q., & Li, Z. (2022) · Exploration · doi:10.1002/exp.20210166 · Cited by 169
Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis
Wang, Q., Zhou, H., Bu, Q., Wei, S., Li, L., Zhou, J., Zhou, S., Su, W., Liu, M., Liu, Z., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.02.031 · Cited by 144
Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response
Sahraei, M., Chaube, B., Liu, Y., Sun, J., Kaplan, A., Price, N. L., Ding, W., Oyaghire, S., García-Milian, R., Mehta, S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127125 · Cited by 139
“This study highlights how the loss of mature miRNAs in TAMs during tumor progression leads to increased classically activated TAMs, improved CD8 response, and decreased CD8 suppression, which was associated with higher expression of CXCL10, CD86, and CXCL9 in the tumors (5).”
InfluentialmiR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy
Xi, J., Huang, Q., Wang, L., Ma, X., Deng, Q., Kumar, M., Zhou, Z., Li, L., Zeng, Z., Young, K. H., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0178-3 · Cited by 143
Zhang, L. L., Jia, Y., Yang, J.-J., Zhang, L., Hou, S., Niu, X., Zhu, J., Huang, Y., Sun, X., Xu, Z. P., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c02183 · Cited by 127
Development of mi RNA ‐based therapeutic approaches for cancer patients
Takahashi, R., Prieto‐Vila, M., Kohama, I., & Ochiya, T. (2019) · Cancer Science · doi:10.1111/cas.13965 · Cited by 140
Mannose receptor modulates macrophage polarization and allergic inflammation through miR-511-3p
Zhou, Y., Do, D. C., Ishmael, F. T., Squadrito, M. L., Tang, H. M., Tang, H. L., Hsu, M.-H., Qiu, L., Li, C., Zhang, Y., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.04.049 · Cited by 138
“It has been evident that miRNAs control the balance ofM1 andM2macrophage polarization and modulate downstream immune responses.(18-20,22,37,38) It is possible that MRC1 can modulate allergen-induced inflammation through controlling the balance of inflammation and anti-inflammation by modulating macrophage polarization…”
BackgroundSelf-citationInflammation as target in cancer therapy
Marelli, G., Sica, A., Vannucci, L. E., & Allavena, P. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.007 · Cited by 133
Shobaki, N., Sato, Y., Suzuki, Y., Okabe, N., & Harashima, H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.001 · Cited by 118
miR-148a-3p Mediates Notch Signaling to Promote the Differentiation and M1 Activation of Macrophages
Huang, F., Zhao, J., Wang, L., Gao, C.-C., Liang, S.-Q., An, D., Bai, J., Chen, Y., Han, H., & Qin, H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01327 · Cited by 123
“reported that depletion of the miRNA-processing enzyme, DICER, in macrophages promotes M1-like TAM programming through hyperactivation of IFN-γ/STAT1 signaling (23).”
BackgroundCircadian regulation of cancer cell and tumor microenvironment crosstalk
Xuan, W., Khan, F., James, C. D., Heimberger, A. B., Lesniak, M. S., & Chen, P. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.06.008 · Cited by 111
Zha, H., Wang, X., Zhu, Y., Chen, D., Han, X., Yang, F., Gao, J., Hu, C., Shu, C., Feng, Y., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0272 · Cited by 106
Dicer in Macrophages Prevents Atherosclerosis by Promoting Mitochondrial Oxidative Metabolism
Wei, Y., Corbalán-Campos, J., Gurung, R., Natarelli, L., Zhu, M., Exner, N., Erhard, F., Greulich, F., Geißler, C., Uhlenhaut, N. H., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.031589 · Cited by 113
IRE1α regulates macrophage polarization, PD-L1 expression, and tumor survival
Batista, A., Rodvold, J. J., Su, X., Searles, S. C., Lew, A., Iwawaki, T., Almanza, G., Waller, T. C., Lin, J. H., Jepsen, K., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000687 · Cited by 111
Martínez-Usatorre, A., Kadioglu, E., Boivin, G., Cianciaruso, C., Guichard, A., Torchia, B., Zangger, N., Nassiri, S., Keklikoglou, I., Schmittnaegel, M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1616 · Cited by 118
Self-citationCortesi, F., Delfanti, G., Grilli, A., Calcinotto, A., Gorini, F., Pucci, F., Lucianò, R., Grioni, M., Recchia, A., Benigni, F., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.058 · Cited by 100
“Conversely, CD11c+/Tie2-negative TAMs express a M1-skewed gene signature and exhibit angiostatic and immunostimulatory functions (Baer et al., 2016; Pucci et al., 2009). r(s). creativecommons.org/licenses/by-nc-nd/4.0/).”
BackgroundInfluentialKiss, M., Walle, L. V., Saavedra, P. H. V., Lebegge, E., Damme, H. V., Murgaski, A., Qian, J., Ehling, M., Pretto, S., Bolli, E., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0431 · Cited by 109
Self-citationCytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy
Ghasemi, A., Martínez-Usatorre, A., Li, L., Hicham, M., Guichard, A., Marcone, R., Fournier, N., Torchia, B., Bedoya, D. M., Davanture, S., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00668-y · Cited by 102
Wang, J., Chang, Y., Luo, H., Jiang, W., Xu, L., Chen, T., & Zhu, X. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120153 · Cited by 98
The role of macrophage phenotype in regulating the response to radiation therapy
Shi, X., & Shiao, S. L. (2017) · Translational research · doi:10.1016/j.trsl.2017.11.002 · Cited by 102
“Two of the most promising approaches to target the M2 phenotype in macrophages include elimination of the DICER protein in macrophages, which leads to overexpression of microRNAs miR-511-3p or miR-26a, both of which inhibit signaling required for M2 polarization and CSF1/CSF1R blockade.(66,67,87) Interestingly, CSF1/C…”
BackgroundOptimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy
Kashyap, A. S., Schmittnaegel, M., Rigamonti, N., Ferreira, D. P., Mueller, P., Buchi, M., Ooi, C.-H., Kreuzaler, M., Hirschmann, P., Guichard, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902145116 · Cited by 96
“ulations was performed and analyzed as recently described by us (22, 47).”
MethodSelf-citationLi, J., Shui, X., Sun, R., Wan, L., Zhang, B., Xiao, B., & Luo, Z. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.736310 · Cited by 88
Freund, E. C., Lock, J. Y., Oh, J., Maculins, T., Delamarre, L., Bohlen, C. J., Haley, B., & Murthy, A. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191692 · Cited by 103
“Strategies targeting myeloid cells have emerged as relevant for promoting antimicrobial or antitumor immunity, making research into the biology or modification of these cell types necessary for advancing immunomodulatory therapeutics (Baer et al., 2016; Broz et al., 2014; Edwards et al., 2019; Kuhn et al., 2013; Kumar…”
BackgroundRole of macrophages in tumor progression and therapy (Review)
Xu, Y., Wang, X., Liu, L., Wang, J., Wu, J., & Sun, C. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5347 · Cited by 94
Sabouni, E., Nejad, M. M., Mojtabavi, S., Khoshdooz, S., Mojtabavi, M., Nadafzadeh, N., Nikpanjeh, N., Mirzaei, S., Hashemi, M., Aref, A. R., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114395 · Cited by 99
Bernstein, D. L., Jiang, X., & Rom, S. (2021) · Biomedicines · doi:10.3390/biomedicines9060606 · Cited by 88
“Such effects may be combinatory and lead to greater inflammation, particularly IFNγ-mediated increases in cell aggregation [56], which can further exacerbate oxidative stress in the area and promote abnormal growth.”
BackgroundBiology and therapeutic targeting of tumour‐associated macrophages
Beltraminelli, T., & De Palma, M. (2020) · The Journal of Pathology · doi:10.1002/path.5403 · Cited by 86
“In transplant mouse models of breast and lung cancer, M1-like immunostimulatory TAMs generally express higher levels of major histocompatibility class II (MHC-II) molecules than their M2-like (immunosuppressive) counterparts and, therefore, may have antigen presentation capacity [8,23,24,56,63].”
BackgroundInfluentialTargeting tumor‐associated macrophages: A potential treatment for solid tumors
Chen, Y., Jin, H., Song, Y., Huang, T., Cao, J., Tang, Q., & Zou, Z. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30139 · Cited by 82
“In the mechanism, they showed that inhibition of DICER reprograms TAMs to antitumor M1 phenotype by upre- gulating IFN‐γ levels (Baer et al., 2016).”
BackgroundBoeri, M., Milione, M., Proto, C., Signorelli, D., Russo, G. L., Galeone, C., Verri, C., Mensah, M., Centonze, G., Martinetti, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1981 · Cited by 89
Liu, Y., Li, X., Zhang, Y., Wang, H., Rong, X., Peng, J., He, L., & Peng, Y. (2019) · Oncogene · doi:10.1038/s41388-019-0952-x · Cited by 83
“For example, miR-511-3p, miR-142-3p, and miR-155-5p have all been shown to suppress M2-TAMs activation in tumors [29].”
BackgroundModulators of MicroRNA Function in the Immune System
Jia, Y., & Wei, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072357 · Cited by 89
“In macrophages, altered miRNA profiles, due to up- or downregulated Dicer expression, modulate macrophage polarization towards either alternatively or classically activated phenotype [20].”
BackgroundWang, Y., Shi, J., Xin, M., Kahkoska, A. R., Wang, J., & Gu, Z. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01230-6 · Cited by 87
“Macrophages can also substantially affect tumour immunotherapeutic responses 187,188 , as M1 macrophages generally cause a positive immune response and enhance antitumour immunity by secreting pro-inflammatory biological molecules such as IL-1 and TNFα 187,189,190 .”
EVIR: chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens
Squadrito, M. L., Cianciaruso, C., Hansen, S. K., & De Palma, M. (2018) · Nature Methods · doi:10.1038/nmeth.4579 · Cited by 77
Self-citationWang, H., Ge, J.-C., Zhang, F., Zha, X., Liu, J., Li, Q.-M., & Luo, J. (2022) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2022.119683 · Cited by 76
Milestones in tumor vascularization and its therapeutic targeting
Palma, M. D., & Hanahan, D. (2024) · Nature Cancer · doi:10.1038/s43018-024-00780-7 · Cited by 87
“IFNγ directly restrains EC proliferation 95 and instigates angiostatic macrophage programming 96 .”
Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment
Chen, W., Shen, L., Jiang, J., Zhang, L., Zhang, Z., Pan, J., Ni, C., & Chen, Z. (2021) · Biomarker Research · doi:10.1186/s40364-021-00312-w · Cited by 79
“CD8 CTLs CD8 CTLs play a key role in inhibiting tumor angiogenesis by secreting IFN-γ [51, 52], which directly inhibits endothelial cell proliferation and tumor vascularization [53] and polarizes M2-like TAMs to an M1-like phenotype [54].”
BackgroundZhang, M., Zhou, Z., Wang, J., & Li, S. (2016) · Immunology Letters · doi:10.1016/j.imlet.2016.10.004 · Cited by 77
Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression
Laplagne, C., Domagala, M., Le Naour, A., Quemerais, C., Hamel, D., Fournié, J.-J., Couderc, B., Bousquet, C., Ferrand, A., & Poupot, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194719 · Cited by 72
“For instance, targeting of miRNA-processing enzyme DICER in macrophages with lysozyme-M-driven Cre prompts M1-like TAM reprogramming in lung carcinoma and MC38 tumors [67].”
BackgroundXu, S., Hu, H.-T., Li, H. L., & Chang, S. (2019) · Cells · doi:10.3390/cells8101140 · Cited by 80
Yin, W., Li, Y., Song, Y. Y., Zhang, J., Wu, C., Chen, Y., Miao, Y., Lin, C., Lin, Y., Yan, D., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2024171118 · Cited by 75
Chen, X., Dong, H., Liu, S., Yu, L., Yan, D., Yao, X., Sun, W., Han, D., & Gao, G. (2017) · PubMed · Cited by 74
Oxidative Stress and Inflammation in Cardiovascular Diseases and Cancer: Role of Non-coding RNAs.
Ginckels, P., & Holvoet, P. (2022) · Lirias (KU Leuven) · Cited by 99
Tumor associated macrophages and ‘NO’
Nath, N., & Kashfi, K. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113899 · Cited by 68
Wang, Q., Li, G., Ma, X., Liu, L., Liu, J., Yin, Y., Li, H., Chen, Y., Zhang, X., Zhang, L., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05609-2 · Cited by 66
Dzobo, K., & Dandara, C. (2020) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2020.0023 · Cited by 66
“Coupling anti-angiogenesis specific therapy with strategies that disrupt any compensatory factors and signaling from cells such as macrophages and neutrophils offers better potential at inhibiting angiogenesis in tumors (Baer et al., 2016; Biswas and Mantovani, 2010; Lewis et al., 2016).”
Mirabelli, M., Misiti, R., Sicilia, L., Brunetti, F. S., CHIEFARI, E. D., Brunetti, A., & FOTI, D. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189802 · Cited by 75
“Emerging evidence suggests that miRNAs, released by adipose cells in exosomes and other vesicles, play crucial roles in maintaining glucose homeostasis and influencing macrophage polarization in a paracrine manner [94,95].”
BackgroundTranscriptional determination and functional specificity of myeloid cells: making sense of diversity
Monticelli, S., & Natoli, G. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.51 · Cited by 72
Ardighieri, L., Missale, F., Bugatti, M., Gatta, L. B., Pezzali, I., Monti, M., Gottardi, S., Zanotti, L., Bignotti, E., Ravaggi, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690201 · Cited by 69
“Of note, STAT1IRF1 TAM have been observed in tumor-bearing mice with DICER conditional deletion (42) and resulted in tumor inhibition by recruitment of activated CTL.”
BackgroundSelf-citationCancer and Microenvironment Plasticity: Double-Edged Swords in Metastasis
Zhuang, X., Zhang, H., & Hu, G. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.04.005 · Cited by 68
Xu, X., Gong, X., Wang, Y., Li, J., Wang, H., Wang, J., Sha, X., Li, Y., & Zhang, Z. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900181 · Cited by 60
Novel insights in the regulation and function of macrophages in the tumor microenvironment
Bolli, E., Movahedi, K., Laoui, D., & Van Ginderachter, J. A. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000344 · Cited by 57
Self-citationAngiogenesis and targeted therapy in the tumour microenvironment: From basic to clinical practice
Yang, S., Fang, Y., Ma, Y., Wang, F., Wang, Y., Jia, J., Yang, Y., Sun, W., Zhou, Q., & Li, Z. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70313 · Cited by 71
CXCR3.1 and CXCR3.2 Differentially Contribute to Macrophage Polarization in Teleost Fish
Lu, X., Chen, Q., Rong, Y.-J., Chen, F., & Chen, J. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700101 · Cited by 55
“In mice, STAT1 is identified as a crucial transcription factor for M1 macrophage polarization (58, 59).”
BackgroundLi, M., Lai, X., Zhao, Y., Zhang, Y., Li, M., Li, D., Kong, J., Zhang, Y., Jing, P., Li, H., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0284-8 · Cited by 57
Leveraging macrophages for cancer theranostics
Liu, L., Li, H., Wang, J., Zhang, J., Liang, X., Guo, W., & Gu, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114136 · Cited by 54
Xie, X., Feng, Y., Zhang, H., Su, Q., Song, T., Yang, G., Li, T., Wei, X., Li, T., Qin, X., et al. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.03.008 · Cited by 57
Cancer cell-derived type I interferons instruct tumor monocyte polarization
Kwart, D., He, J., Srivatsan, S., Lett, C., Golubov, J., Oswald, E. M., Poon, P., Ye, X., Waite, J. C., Zaretsky, A. G., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111769 · Cited by 54
Zhang, Y., Zhao, Y., Li, Q., & Wang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.685978 · Cited by 57
“Studies have shown that M1-type macrophages can promote tumor immunity by recruiting cytotoxic T cells (49).”
BackgroundImpact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function
Seifert, M., Benmebarek, M.-R., Briukhovetska, D., Märkl, F., Dörr, J., Cadilha, B. L., Jobst, J., Stock, S., Andreu-Sanz, D., Lorenzini, T., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02013-z · Cited by 54
Kulakova, K. A., Lawal, T. R., McCarthy, E. M., & Floudas, A. (2024) · Cells · doi:10.3390/cells13181586 · Cited by 59
“The polarisation of macrophages towards an M1 or M2 phenotype is a precisely regulated process consisting of several key signalling pathways, transcriptional epigenetic and post-transcriptional regulatory networks [52].”
Background
Metadata
- Authors
- Baer, C., Squadrito, M. L., Laoui, D., Thompson, D., Hansen, S. K., Kiialainen, A., Hoves, S., Ries, C. H., Ooi, C.-H., & De Palma, M.
- Affiliations
- École Polytechnique Fédérale de Lausanne (CH)
- F. Hoffmann-La Roche AG (CH)
- Roche Pharma AG (Germany) (DE)
- Corresponding author
- Squadrito, Mario Leonardo
- ORCID
- Venue
- Nature Cell Biology
- Published
- 2016-06-13
- Volume
- 18
- Issue
- 7
- Pages
- 790-802
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- OpenAlex
- W2436603111
- Cited by
- 259
- References
- 71
- Citations by year
- 2026: 8 · 2025: 17 · 2024: 24 · 2023: 15 · 2022: 37 · 2021: 36 · 2020: 35 · 2019: 26 · 2018: 32 · 2017: 20 · 2016: 8
- FWCI
- 17.35
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (tdm)
- Locations
- Nature Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Keywords
- tumour-associated macrophages, microRNA processing, Dicer, let-7 microRNA, M1 macrophage polarization, M2 macrophage phenotype, antitumor immunity, cytotoxic T lymphocytes, anti-PD-1 therapy, CSF1R blockade, macrophage depletion, tumor immunosuppression
- MeSH terms
- Animals, Cells, Cultured, Humans, Interferon-gamma, Macrophage Activation, Macrophages, Neoplasms, MicroRNAs, Ribonuclease III, Mice, DEAD-box RNA Helicases, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.